Volume 84, Issue 3, Pages 578-584 (September 2013) Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs  Werner Kleophas, Angelo Karaboyas, Yun Li, Juergen Bommer, Helmut Reichel, Andreas Walter, Andrea Icks, Lars C. Rump, Ronald L. Pisoni, Bruce M. Robinson, Friedrich K. Port  Kidney International  Volume 84, Issue 3, Pages 578-584 (September 2013) DOI: 10.1038/ki.2013.143 Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 1 German quality assurance program. Trends in crude prevalences of German quality assurance (QA) program measures. Kidney International 2013 84, 578-584DOI: (10.1038/ki.2013.143) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 2 Trends in crude prevalences. (a) Trends in crude prevalences of erythropoietin-stimulating agent (ESA) and intravenous (IV) iron prescription. (b) Trends in crude prevalences of ESA and IV iron dose; *ESA dose among patients prescribed ESA and IV iron dose among patients prescribed iron. Kidney International 2013 84, 578-584DOI: (10.1038/ki.2013.143) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 3 Trends in crude prevalences. (a) Trends in crude prevalences of low hemoglobin (<10g/dl) for France, Germany, Spain, and the United Kingdom. (b) Trends in crude prevalences of low Kt/V (<1.2) for France, Germany, Spain, and the United Kingdom. (c) Trends in crude prevalences of low treatment time (TT; <4h) for France, Germany, Spain, and the United Kingdom. (d) Trends in crude prevalences of low number of sessions/week (<3) for France, Germany, Spain, and the United Kingdom. No data were available from France in 2005 and the United Kingdom in 2009. Kidney International 2013 84, 578-584DOI: (10.1038/ki.2013.143) Copyright © 2013 International Society of Nephrology Terms and Conditions